our research and development footprint and outsourced certain functions that do not drive competitive advantage for Pfizer.

Our development pipeline, which is updated quarterly, can be found at www.pfizer.com/pipeline. It includes an overview of our research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action. The information currently in our development pipeline is accurate as of February 28, 2013.

The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.

      RECENT FDA APPROVALS

   PRODUCT

Eliquis (Apixaban)(a)

Xeljanz (Tofacitinib)

Bosulif (Bosutinib)

Lyrica (Pregabalin) Capsules CV Elelyso (Taliglucerase Alfa)(b) Inlyta (Axitinib)

INDICATION

DATE APPROVED

December 2012

November 2012 September 2012 June 2012

May 2012 January 2012

   Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Treatment of moderate-to-severe active rheumatoid arthritis

Treatment of previously treated chronic myelogenous leukemia

Treatment of neuropathic pain due to spinal cord injury

Treatment of adults with a confirmed diagnosis of type 1 Gaucher disease

Treatment of advanced renal cell carcinoma after failure of one prior systemic therapy

                   (a) This indication for Eliquis (apixaban) was developed and is being commercialized in collaboration with BMS.

(b) In November 2009, we entered into a license and supply agreement with Protalix BioTherapeutics, which provides us exclusive worldwide rights, except in

Israel, to develop and commercialize Elelyso (taliglucerase alpha) for the treatment of Gaucher disease.

   PENDING U.S. NEW DRUG APPLICATIONS (NDA) AND SUPPLEMENTAL FILINGS INDICATION

Treatment of symptoms associated with menopause and osteoporosis

Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP)

Replacement of human growth hormone deficiency (Mark VII multidose disposable device)

Chronic pain

Management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time

Respimat device for chronic obstructive pulmonary disease

Osteoporosis treatment and prevention

* The dates set forth in this column are the dates on which the FDA accepted our submissions.

   PRODUCT

Bazedoxifene-conjugated estrogens

Tafamidis meglumine(a) Genotropin(b)

Celebrex(c) Remoxy(d)

DATE FILED*

December 2012

February 2012 December 2009

October 2009 August 2008

January 2008 August 2006

                  Spiriva(e) Viviant(f)

      (a) In May 2012, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a “complete response” letter with respect to the tafamidis NDA. The FDA has requested the completion of a second efficacy study and